ChiCTR2100053602
Untitled Trial
Efficacy and safety of amtenofovir in patients with ALT normal chronic hepatitis B infection: a prospective, randomized, blank-controlled, multicenter clinical study
Ruijin Hospital, Shanghai Jiaotong University School of Medicine·Phase 4·Chinese Clinical Trial RegistryNot yet recruiting
View on Chinese Clinical Trial Registry →Study focus
- Disease/Condition
- Hepatitis B
- Drug/Device/Intervention
- Patients meeting the admission criteria were randomly assigned to group A or group B: Group A (TMF treatment group): from day 1 of week 1, orally, once A day, 25mg each time, 133 patients were expected to be enrolled; Group B (blank control group): 133 patients were expected to be enrolled as blank control group without any antiviral treatment.
Sponsor & location
- Primary sponsor
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
- Funder
- Supported by Jiangsu Hausen Pharmaceutical Group Co., LTD
- Location
- China
Timeline & enrollment
- Phase
- Phase 4
- Start date
- N/A
- End date
- Nov 26, 2024
ICD-10 classifications
Acute hepatitis BAcute hepatitis B without delta-agent and without hepatic comaAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agentChronic viral hepatitis B without delta-agent : other and unspecified phase
Data source
- Registry
- Chinese Clinical Trial Registry
- Trial ID
- ChiCTR2100053602
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for ChiCTR2100053602 through Pure Global AI's free database. This Phase 4 trial is sponsored by Ruijin Hospital, Shanghai Jiaotong University School of Medicine and is currently Not yet recruiting. The study focuses on Hepatitis B.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.